Recent Updates — SCYX

SCYNEXIS, Inc. entered into a material definitive agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of SCY-247, its second-generation antifungal candidate. The contract provides up to $214 million in potential non-dilutive funding if all options are exercised, with an initial base period commencing in September 2026 providing approximately $18.5 million. These funds will advance oral and intravenous SCY-247 into a Phase 2 study for invasive candidiasis, with the possibility of extending development through New Drug Application submissions for two indications over up to ten years. The company expects to fund its share of near-term costs within existing operating plans, leaving its cash runway into 2029 and SCY-770 development plans unchanged. SCYNEXIS is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases.

SCYNEXIS, Inc. appointed Steven K. Burke, M.D., to its Board of Directors effective September 18, 2026. Dr. Burke joins the Nominating and Corporate Governance Committee and receives an annual retainer of $45,000 plus committee fees. His compensation includes initial grants of 5,750 stock options at $4.46 per share and 5,750 restricted stock units, along with recurring annual equity awards. Dr. Burke brings over 30 years of biopharmaceutical experience, currently serving as Senior Vice President and Chief Medical Officer at Akebia Therapeutics, Inc., where he leads drug development for chronic kidney disease. SCYNEXIS is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases.

SCYNEXIS, Inc. announced the retirement of Chief Financial Officer Ivor Macleod and the appointment of Sanjay Subramanian as his successor, effective September 9, 2026. Mr. Macleod will remain with the company through October 9, 2026 to facilitate a transition. Mr. Subramanian’s employment agreement includes an annual base salary of $500,000, a one-time sign-on bonus of $20,000, and a discretionary performance bonus of up to 40% of his base salary. He received a stock option to purchase 100,000 shares at an exercise price of $4.91 per share, vesting over four years. The agreement also outlines severance provisions, including nine months of base salary and accelerated equity vesting upon termination without cause or for good reason, increasing to eighteen months following a change of control. SCYNEXIS operates in the biotechnology industry, developing innovative therapies for severe rare diseases.

SCYNEXIS, Inc. stockholders at the June 25, 2026 Annual Meeting approved an amendment to its Certificate of Incorporation to increase the total number of authorized shares of Common Stock to 60,000,000 shares (pre-reverse stock split). The company also filed a Registration Statement on Form S-3 to register the resale of up to 87,000,000 shares of Common Stock, including shares held by selling stockholders and shares issuable upon the exercise of pre-funded and common warrants. SCYNEXIS, Inc. is a biotechnology company focused on developing and commercializing specialty antibiotic treatments.